Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-05-23, Stock:LLY, The news for the past five days is as follows:
2018-05-16: NEWS1: Lilly Data at ASCO Illustrate Patient-Driven Advances in Cancer Care.NEWS2: Eli Lilly's Cluster Headache Candidate Succeeds in Phase III.NEWS3: Eli Lilly's Cluster Headache Candidate Succeeds in Phase III.NEWS4: iShares Core High Dividend ETF Experiences Big Outflow.NEWS5: iShares Core High Dividend ETF Experiences Big Outflow.NEWS6: Eli Lilly&apos;s Cluster Headache Candidate Succeeds in Phase III.NEWS7: LLY Gets Headache Relief, XENE Abuzz, 3rd Time's A Charm For PFE's Epogen Biosim.NEWS8: LLY Gets Headache Relief, XENE Abuzz, 3rd Time's A Charm For PFE's Epogen Biosim.
2018-05-17: NEWS1: U.S. FDA approves Amgen migraine drug, price set at $6900/yr.NEWS2: Roche Tecentriq Combo Achieves Longer Overall Survival Rate.NEWS3: Roche Tecentriq Combo Achieves Longer Overall Survival Rate.NEWS4: Exelixis Is Expected to Report a Robust Revenue Rise in 2018.NEWS5: Teva’s Fiscal Guidance: Confidence in Its Growth.NEWS6: Wired News – Eli Lilly’s Galcanezumab Met Primary Endpoint in Phase-3 Study for Prevention of Episodic Cluster Headache.
2018-05-18: NEWS1: Eli Lilly’s Business Segments in Q1 2018.NEWS2: Eli Lilly’s Revenue Trend in Q1 2018.NEWS3: Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug.NEWS4: Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug.NEWS5: Eli Lilly’s Valuation on May 17.NEWS6: Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug.NEWS7: Amgen's Migraine Drug Aimovig Gets FDA Approval, Shares Up.NEWS8: Amgen's Migraine Drug Aimovig Gets FDA Approval, Shares Up.NEWS9: AstraZeneca's (AZN) Q1 Earnings & Sales Miss, Stock Down.NEWS10: AstraZeneca's (AZN) Q1 Earnings & Sales Miss, Stock Down.NEWS11: Amgen, Novartis Clinch FDA Nod on Migraine Prevention Drug.NEWS12: AstraZeneca&apos;s (AZN) Q1 Earnings & Sales Miss, Stock Down.NEWS13: 5 Things AbbVie Investors Need to Know.NEWS14: 5 Things AbbVie Investors Need to Know.
2018-05-21: NEWS1: Migraine Space in Focus as AMGN/NVS' Aimovig Gets FDA Nod.NEWS2: Migraine Space in Focus as AMGN/NVS' Aimovig Gets FDA Nod.NEWS3: Eli Lilly’s Neuroscience Products in Q1 2018.NEWS4: Eli Lilly’s Human Pharmaceuticals Business in Q1 2018.NEWS5: Bristol-Myers Squibb and Three Additional Stocks Under Scanner in the Drug Makers Space.
2018-05-22: NEWS1: Why Did JNJ Scrap Its Alzheimer’s Drug Mid-Stage Trial?.NEWS2: Amgen's Label Expansion Application for Prolia Gets FDA Nod.NEWS3: Amgen's Label Expansion Application for Prolia Gets FDA Nod.NEWS4: Eli Lilly’s Elanco in Q1 2018.NEWS5: Eli Lilly’s Cardiovascular Products in Q1 2018.NEWS6: Lilly's Taltz® (ixekizumab) Receives the First U.S. FDA Approval for Label Update to Include Data for Psoriasis Involving the Genital Area.NEWS7: Eli Lilly’s Oncology Products in Q1 2018.NEWS8: Eli Lilly And Co. To Present At UBS Global Conference; Webcast At 10:30 AM ET.NEWS9: Eli Lilly And Co. To Present At UBS Global Conference; Webcast At 10:30 AM ET.NEWS10: Eli Lilly: FDA Approves Label Update For Taltz - Quick Facts.NEWS11: Eli Lilly: FDA Approves Label Update For Taltz - Quick Facts.

Answer: Rise